Mary Hobart
About Mary Hobart
Mary Hobart is the Vice President of Global Regulatory Affairs at Otsuka Pharmaceutical Development & Commercialization, Inc., with over 25 years of experience in various medical fields.
Mary Hobart Title and Position
Mary Hobart is the Vice President of Global Regulatory Affairs at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). In this role, she oversees and directs the global medical and regulatory strategy for the company. Her responsibilities include compliance with international regulatory standards, strategic planning, and coordination with various stakeholders to ensure successful drug development and commercialization.
Mary Hobart Professional Experience
Mary Hobart has accumulated over 25 years of extensive experience in clinical, academic, and pharmaceutical medicine, as well as drug development. Her multifaceted career spans several high-impact roles where she has been deeply involved in the regulatory aspects of pharmaceutical developments. This wealth of experience equips her with a comprehensive understanding of the regulatory landscape and its critical intersection with medical and scientific advancement.
Mary Hobart at Otsuka Pharmaceutical Development & Commercialization
At Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Mary Hobart is responsible for devising and implementing the global medical and regulatory strategy. Her role is central to ensuring that the products developed are in compliance with global regulatory standards, leading to successful market entry and patient access. This involves strategic planning, liaison with regulatory bodies, and coordinating with internal and external stakeholders to navigate the complex drug development and approval processes.